Evoke Pharma Inc
Evoke Pharma Inc (EVOK): 2 pipeline candidates · ~73 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
73.4 months
D/E 3.65 · 48% dilution
Lead: Approved
2 candidates
N/A
N/A
A transparent, data-derived signal for Evoke Pharma Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$11.6M
Quarterly Burn
$522K
Runway
73.4 mo
Revenue
$4.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| evox system | — |
| gimoti | Approved |
Frequently asked questions
How many drug candidates are in Evoke Pharma Inc's pipeline?
Evoke Pharma Inc (EVOK) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Evoke Pharma Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Evoke Pharma Inc has approximately 73.4 months of cash runway.
Who is the CEO of Evoke Pharma Inc?
Solana Beach is the chief executive officer of Evoke Pharma Inc (EVOK).
Get the full picture on Evoke Pharma Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.